Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on February 9, 2006
Schizophrenia Bulletin 2006 32(4):692-700; doi:10.1093/schbul/sbj050
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
32/4/692    most recent
sbj050v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Potter, D.
Right arrow Articles by Buchanan, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Potter, D.
Right arrow Articles by Buchanan, R. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Review of Clinical Correlates of P50 Sensory Gating Abnormalities in Patients with Schizophrenia

David Potter2, Ann Summerfelt3, James Gold3 and Robert W. Buchanan1,3
2 University of Maryland School of Medicine, Department of Psychiatry, Baltimore, Maryland
3 Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland

1To whom correspondence should be addressed; Maryland Psychiatric Research Center, P.O. Box 21247, Baltimore, MD 21228; tel: 410-402-7876, fax: 410-402-7198, e-mail: rwbuchanan{at}mprc.umaryland.edu

A large percentage of patients with schizophrenia are characterized by an abnormality in P50 sensory gating. This abnormality has been shown to be genetically linked to the {alpha}-7 nicotinic receptor and is transiently reversed by acute nicotine administration. These observations have led to the development of pharmacological treatments designed to improve sensory gating. However, if normalization of P50 gating abnormalities is to guide drug development, then it becomes important to delineate the clinical correlates of enhanced P50 gating. We conducted a review of all available articles through March 2005 that have examined this issue. We found that, despite the prominent role that P50 abnormalities have played in our understanding of schizophrenia, there is a relative dearth of data examining P50 clinical correlates. There is evidence suggestive of an association between P50 and measures of attention, and multiple studies have failed to document a cross-sectional or longitudinal relationship between P50 and positive, negative, or other symptoms. These results suggest that considerably more work needs to be done to understand and validate the clinical significance of this impairment.

Keywords: schizophrenia / sensory gating / neuropsychological tests / symptoms / antipsychotics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Schizophr BullHome page
G. K. Thaker
Neurophysiological Endophenotypes Across Bipolar and Schizophrenia Psychosis
Schizophr Bull, July 1, 2008; 34(4): 760 - 773.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.